Question-and-Answer Session
Operator
(Operator Instructions) Your first question comes from the line of Jim Birchenough from Barclays Capital. Please proceed sir.
Ryan Martins - Barclays Capital
Hi, actually this is Ryan Martins in for Jim Birchenough, thanks for taking my call. I was wondering if you guys could give us some additional color or update on the programs behind sarcoma, that’s the prostate, endometrial and breast programs.
Harvey Berger
What sort of information would you like? I’m not sure what you’re aiming for.
Ryan Martins - Barclays Capital
More in terms of what we can expect, in terms of timelines on data.
Harvey Berger
Well, what we just said and what is our focus is getting to be in a position to have initial clinical data, first in endometrial and breast cancer; obviously, that would be followed by the data in prostate and non-small cell lung cancer. The order is largely driven by when this trial started and the size of the trials, so our goal is to have at some point this year, the initial Phase II data with respect to breast for starters and endometrial cancer potentially.
We don’t expect the prostate or non-small cell lung cancer data in the near term, namely in this year, because those trials started either in the case of prostate in the fourth quarter of last year or in the case of non-small cell lung cancer just starting. So the two most advanced trials of those four Phase II trials are in endometrial and breast cancer.
There are two trials running in endometrial cancer, one a cooperative group trial run by the NCIC in Canada and the other run by ARIAD and Merck. The breast cancer trial is moving along well, as are all of these trials. So we will have data as soon as enrollment is far enough along and we are first focused in the first two trials that started initially.
Ryan Martins - Barclays Capital
Sure, and just another question related to the sarcoma trial. Have you already had the first interim analysis? I know it was projected sometime first quarter.
Harvey Berger
We’ll announce the results, information relating to the first interim analysis when it’s completed. It’s not been announced to date. We expect it to happen sometime in the early part of this year. It is driven first and foremost by the timing of events that is the time when patients in the trial, progress. Obviously, first it’s driven by enrollment that we have control over and enrollment in turn provides the basic data that can lead to a certain number of events.
- To read the full transcript on Seeking Alpha, click here »
